These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [CEA and TPA in cancer of the breast. Findings and criteria of use].
    Author: Torres Avisbal M, Ruíz de Almodovar Rivera JM, Villalba Moreno J, Olea Serrano N, Padilla Bolivar O, Pedraza Muriel V.
    Journal: Rev Esp Oncol; 1985; 32(2):265-80. PubMed ID: 3843460.
    Abstract:
    In breast cancer, under rigorous and normalized conditions, the blood levels of carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) allow us: to differentiate with enough precision, in treated patients, the presence of tumour (EP) from illness-free situation (NED); to alert about the appearance of metastases and/or local relapse in patients put under systematic postoperative evolutional control; to evaluate the systemic palliative treatment response in patients with metastatic breast cancer and to formulate, in this case, prognostic predictions. Blood levels of CEA and TPA are, otherwise, unsuitable: to detect with accuracy the primary tumour presence; to warn about the risk of subclinical tumour existence (in treated patients in NED situation); to predict, in this last case, the chemotherapeutic treatment response, and to prevent about local relapses development. The independent but combined use of both antigens, appreciably raises the diagnostic success percentage with regard to that obtained when only one tumour marker was used.
    [Abstract] [Full Text] [Related] [New Search]